Product/Composition:- | Sofosbuvir & Ledipasvir |
---|---|
Strength:- | Sofosbuvir 400 mg & Ledipasvir 90 mg |
Form:- | Tablet |
Reference Brands:- | Harvoni®(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sofosbuvir & Ledipasvir Tablets (400/90 mg) treat Hepatitis C with high cure rates. Available under brands like Harvoni®, Ledifos®, and Hepcinat-LP®, they can be bulk-sourced via PharmaB2B platforms from WHO-GMP-approved manufacturers for tenders, NGOs, and HCV treatment programs worldwide.
Sofosbuvir & Ledipasvir Tablets (400 mg/90 mg) are a powerful, once-daily combination therapy for chronic Hepatitis C. Marketed under global brands like Harvoni®, Ledifos®, and Hepcinat-LP®, this fixed-dose antiviral regimen is recommended by WHO and major liver associations. It offers high cure rates with minimal side effects across genotypes 1, 4, 5, and 6. On PharmaB2B platforms, global buyers can source WHO-GMP and USFDA-approved generic alternatives from trusted Indian manufacturers. Ideal for institutional procurement, NGO supply, and public health programs, Sofosbuvir + Ledipasvir helps scale access to life-saving HCV treatment worldwide.